Adalimumab biosimilar - Oncobiologics

Drug Profile

Adalimumab biosimilar - Oncobiologics

Alternative Names: ONS-3010

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncobiologics
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase I Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 14 Feb 2018 Oncobiologics announces intention to submit NDA to US FDA in 2021
  • 14 Feb 2018 Oncobiologics plans phase III trials for Crohn's disease, Psoriasis, Rheumatoid arthritis and Ulcerative colitis in emerging markets in Q3/Q4 2018
  • 14 Feb 2018 Oncobiologics plans phase III trials in major markets in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top